Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ACET

ACET - Adicet Bio, Inc. Stock Price, Fair Value and News

2.33USD-0.06 (-2.51%)Market Closed
Watchlist

Market Summary

USD2.33-0.06
Market Closed
-2.51%

ACET Alerts

  • Carlyle Group Inc. reported owning 4.1% of ACET [2024-02-07]
  • 2 major insider buys recently.

ACET Stock Price

View Fullscreen

ACET RSI Chart

ACET Valuation

Market Cap

100.6M

Price/Earnings (Trailing)

-1.47

Price/Sales (Trailing)

1.75

EV/EBITDA

0.6

Price/Free Cashflow

-1.01

ACET Price/Sales (Trailing)

ACET Profitability

EBT Margin

-209.28%

Return on Equity

-35.26%

Return on Assets

-29.42%

Free Cashflow Yield

-99.32%

ACET Fundamentals

ACET Revenue

Revenue (TTM)

68.3M

ACET Earnings

Earnings (TTM)

-68.6M

Earnings Growth (Yr)

-126.79%

Earnings Growth (Qtr)

-53.95%

Breaking Down ACET Revenue

Last 7 days

-10.1%

Last 30 days

-11.7%

Last 90 days

145%

Trailing 12 Months

-63.7%

How does ACET drawdown profile look like?

ACET Financial Health

Current Ratio

9.4

ACET Investor Care

Shares Dilution (1Y)

0.73%

Diluted EPS (TTM)

-3.35

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202238.7M33.9M73.8M68.3M
202115.9M13.8M11.8M9.7M
20205.2M9.4M13.7M17.9M
20196.4M4.6M2.8M995.0K
20180008.2M

Tracking the Latest Insider Buys and Sells of Adicet Bio, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jan 25, 2024
gordon carl l
bought
7,500,000
2.4
3,125,000
-
Jan 25, 2024
orbimed advisors llc
bought
7,500,000
2.4
3,125,000
-
Jan 24, 2024
aftab blake
acquired
-
-
19,700
chief scientific officer
Jan 24, 2024
harvey brian nicholas
acquired
-
-
26,300
chief financial officer
Jan 24, 2024
aftab blake
sold (taxes)
-8,556
2.4
-3,565
chief scientific officer
Jan 24, 2024
galimi francesco
sold (taxes)
-11,896
2.4
-4,957
svp & chief medical officer
Jan 24, 2024
harvey brian nicholas
sold (taxes)
-10,368
2.4
-4,320
chief financial officer
Jan 24, 2024
schor chen
sold (taxes)
-36,696
2.4
-15,290
president & ceo
Jan 24, 2024
healey don
acquired
-
-
19,700
chief technology officer
Jan 24, 2024
galimi francesco
acquired
-
-
26,300
svp & chief medical officer

1–10 of 50

Which funds bought or sold ACET recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
reduced
-85.46
-156,000
39,000
-%
Feb 15, 2024
Legal & General Group Plc
unchanged
-
1,412
5,167
-%
Feb 15, 2024
JANE STREET GROUP, LLC
new
-
43,492
43,492
-%
Feb 15, 2024
BARCLAYS PLC
added
664
72,000
79,000
-%
Feb 15, 2024
WEXFORD CAPITAL LP
new
-
28,218
28,218
0.01%
Feb 14, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC
reduced
-78.01
-237,832
103,572
-%
Feb 14, 2024
HOLLENCREST CAPITAL MANAGEMENT
unchanged
-
156
567
-%
Feb 14, 2024
TWO SIGMA INVESTMENTS, LP
added
60.1
373,087
681,770
-%
Feb 14, 2024
SEI INVESTMENTS CO
new
-
58,613
58,613
-%

1–10 of 46

Are Funds Buying or Selling ACET?

Are funds buying ACET calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ACET
No. of Funds

Unveiling Adicet Bio, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 27, 2024
millennium management llc
5.2%
3,946,142
SC 13G
Feb 14, 2024
ecor1 capital, llc
0%
0
SC 13G/A
Feb 14, 2024
rtw investments, lp
9.6%
4,134,631
SC 13G/A
Feb 14, 2024
tang capital partners lp
7.8%
5,900,000
SC 13G/A
Feb 12, 2024
morgan stanley
6.4%
2,777,725
SC 13G
Feb 07, 2024
carlyle group inc.
4.1%
3,060,292
SC 13D/A
Feb 07, 2024
blackrock inc.
3.0%
2,111,898
SC 13G/A
Feb 05, 2024
ra capital management, l.p.
9.99%
7,696,949
SC 13G
Feb 02, 2024
cowen financial products llc
6.29%
2,715,278
SC 13G/A
Jan 31, 2024
blackrock inc.
5.1%
2,182,675
SC 13G/A

Recent SEC filings of Adicet Bio, Inc.

View All Filings
Date Filed Form Type Document
Feb 27, 2024
SC 13G
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 12, 2024
SC 13G
Major Ownership Report
Feb 07, 2024
SC 13D/A
13D - Major Acquisition
Feb 07, 2024
SC 13G/A
Major Ownership Report
Feb 05, 2024
SC 13G
Major Ownership Report
Feb 02, 2024
SC 13G/A
Major Ownership Report
Jan 31, 2024
SC 13G/A
Major Ownership Report

Peers (Alternatives to Adicet Bio, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
36.8B
6.8B
-16.59% -47.80%
-7.82
5.38
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.5B
1.8B
-23.99% -31.71%
-44.39
10.69
76.23% 61.08%
17.2B
2.4B
-4.89% -18.90%
102.64
7.11
15.42% 18.43%
13.5B
3.7B
-7.62% -26.87%
22.54
3.64
8.87% 75.42%
MID-CAP
8.2B
396.6M
-2.06% 34.31%
-15.49
20.64
425.83% 18.94%
6.0B
-
-3.85% 226.12%
-9.55
60.35
54.84% -25.61%
4.2B
240.7M
-19.08% -10.99%
-14.19
17.5
-1.03% -92.09%
3.9B
270.6M
8.92% 47.81%
-16.43
14.52
440.80% -27.84%
3.9B
631.9M
-12.60% 32.37%
-26.2
6.17
23.54% 31.53%
SMALL-CAP
1.6B
348.4M
-3.38% -9.50%
25.02
4.46
81.69% -7.29%
521.5M
1.0B
-9.17% -57.89%
-0.95
0.5
-43.15% 58.48%
192.2M
4.9M
-14.18% -58.18%
-1.17
39.32
-57.57% 50.48%
123.2M
881.7K
289.54% 381.25%
-2.6
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Adicet Bio, Inc. News

Latest updates
Yahoo Finance11 hours ago
Business Wire22 Jan 202408:00 am
InvestorsObserver05 Jan 202408:00 am

Adicet Bio, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue-100.0%-43,360,000-24,990,0005,468,0003,429,0004,814,0005,112,0005,410,0003,028,0007,465,0002,000,000-----
Operating Expenses37.3%31,565,00022,985,00022,707,00020,284,00021,010,00017,139,00015,641,00017,373,00014,759,00016,683,00016,095,0009,557,0001,245,5008,178,00019,169,00011,691,000-10,200,000
  S&GA Expenses2.1%6,550,0006,415,0006,529,0006,801,0006,352,0005,213,0005,025,0005,630,0005,076,0007,741,0007,419,0002,524,0002,006,5001,847,0002,616,0002,839,0001,799,000
  R&D Expenses51.0%25,015,00016,570,00016,178,00013,483,00014,658,00011,926,00010,616,00011,743,0009,683,0008,942,0008,676,0007,033,000-761,0006,331,00016,553,0008,852,000-11,999,000
EBITDA Margin-34.8%-0.98-0.73-1.36-0.89-6.21-4.57-3.95-3.30-2.13--------
Interest Expenses44.4%26,00018,00018,00018,00025,00050,00051,00050,000-50,00034,000------
Income Taxes------11,00011,000-77,000-48,000-139,0003,000--2,679,0003,00012,00010,0009,000-
Earnings Before Taxes-35.8%-29,874,500-21,996,000-22,538,0004,618,000-15,824,000-14,002,000-10,931,000-21,367,000-9,097,000-14,776,000-8,455,000-7,165,0004,740,500-14,778,000-18,322,000-11,060,00021,969,000
EBT Margin-35.2%-1.02-0.76-1.41-0.93-6.38-4.71-4.07-3.39-2.21--------
Net Income302.5%44,533,500-21,996,000-22,538,0004,618,000-15,813,000-14,013,000-10,854,000-21,319,000-8,958,000-14,779,000-8,455,000-4,486,000-28,890,000-14,778,000-2,651,000-4,131,000-5,757,000
Net Income Margin108.9%0.07-0.75-1.41-0.93-6.37-4.68-4.05-3.37-2.05--------
Free Cashflow-25.8%-25,327,000-20,139,000-17,554,0001,473,000-16,522,000-16,862,000-14,910,000-15,804,000-13,705,000--------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-16.0%23327830533135433034033925726928215415074.0078.0082.00122137145110117
  Current Assets-10.9%18620923526128626428228219921622910011774.0078.0064.00121136145110117
    Cash Equivalents-10.8%18320523225828326127827819220922289.0085.0018.007.0015.0023.0021.007.009.0023.00
  Net PPE-4.4%28.0030.0030.0029.0027.0023.0018.0015.0011.0011.003.003.002.000.000.002.000.000.000.000.000.00
  Goodwill-100.0%-19.0019.0019.0019.0019.0019.0019.0019.0019.0020.0020.0021.00--------
Liabilities0.0%39.0039.0039.0038.0037.0037.0029.0036.0040.0040.0046.0044.0033.004.003.0028.0012.0010.005.006.008.00
  Current Liabilities4.9%20.0019.0018.0020.0017.0016.0010.0016.0020.0021.0025.0022.0030.004.003.0015.0012.0010.005.006.008.00
Shareholder's Equity-18.6%19523926629231829331130321722823611011710.0010.009.009.009.008.008.00109
  Retained Earnings-16.6%-351-301-268-238-208-186-163-168-152-138-127-106-97.37-166-161-69.65-125-100-82.46-71.39-65.64
  Additional Paid-In Capital1.0%5465405355305264804754713703673642162142382379.00235228223176175
Shares Outstanding0.1%43.0043.0043.0043.0042.0040.0040.0040.0030.0032.0026.0040.00---------
Float------428---226---40.00---278---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations14.7%-21,238-24,899-24,094-18,837-15,328-14,7054,105-13,444-9,684-12,778-15,146-13,345-7,849-12,006-8,352-7,2595,601-14,175-12,0499,625-10,718
  Share Based Compensation10.7%5,5605,0234,7654,2504,1914,3354,3504,2802,5292,6593,0431,6473,11652.0029939714.0014.0066377314.00
Cashflow From Investing39.9%-906-1,507-1,915-6,490-4,811-2,849-2,632-3,078-7,178-3827,84212,44874,64623,6784,445-5,014-33,26524,976-34,62876,568-17,779
Cashflow From Financing-126.1%-59.00226-7.0030442,176163-1,13497,463362-27.00144,887267144-15042.00-12326,7023,55046,816-78,892-

ACET Income Statement

2023-09-30
Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]    
Revenue related party$ 0$ 0$ 0$ 24,990
Operating expenses:    
Research and development26,16716,57081,28446,231
General and administrative6,6336,41519,72619,745
Goodwill impairment19,462019,4620
Total operating expenses52,26222,985120,47265,976
Loss from operations(52,262)(22,985)(120,472)(40,986)
Interest income2,5201,2247,8001,581
Interest expense(1)(18)(25)(54)
Other expense, net(142)(217)(472)(456)
Loss before income tax provision(49,885)(21,996)(113,169)(39,915)
Income tax provision0000
Net loss$ (49,885)$ (21,996)$ (113,169)$ (39,915)
Net loss per share attributable to common stockholders, basic$ (1.16)$ (0.53)$ (2.63)$ (0.98)
Net loss per share attributable to common stockholders, diluted$ (1.16)$ (0.53)$ (2.63)$ (0.98)
Weighted-average common shares used in computing net income (loss) per share attributable to common stockholders, basic42,980,64141,642,81543,001,90140,547,792
Weighted-average common shares used in computing net income (loss) per share attributable to common stockholders, diluted42,980,64141,642,81543,001,90140,547,792

ACET Balance Sheet

2023-09-30
Consolidated Balance Sheets (unaudited) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 183,257$ 257,656
Prepaid expenses and other current assets2,6263,382
Total current assets185,883261,038
Property and equipment, net28,27328,710
Operating lease right-of-use asset18,18520,269
Goodwill019,462
Other non-current assets9161,211
Total assets233,257330,690
Current liabilities:  
Accounts payable4,0664,404
Accrued and other current liabilities12,57412,811
Operating lease liability3,1282,492
Total current liabilities19,76819,707
Operating lease liability, net of current portion18,66918,531
Other non-current liabilities143114
Total liabilities38,58038,352
Commitments and contingencies (Note 10)
Stockholders’ equity:  
Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of September 30, 2023 and December 31, 2022, respectively; none issued and outstanding as of September 30, 2023 and December 31, 2022, respectively00
Common stock, $0.0001 par value, 150,000,000 shares authorized as of September 30, 2023 and December 31, 2022, respectively; 43,107,921 and 42,954,820 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively44
Additional paid-in capital545,956530,448
Accumulated deficit(351,283)(238,114)
Total stockholders’ equity194,677292,338
Total liabilities and stockholders’ equity$ 233,257$ 330,690
ACET
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and chimeric adaptors to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also develops ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors; and ADI-925, a novel engineered CAd gamma delta T cell product candidate targeting tumor stress ligands. Adicet Bio, Inc. is based in Boston, Massachusetts.
 CEO
 WEBSITEwww.adicetbio.com
 EMPLOYEES132

Adicet Bio, Inc. Frequently Asked Questions


What is the ticker symbol for Adicet Bio, Inc.? What does ACET stand for in stocks?

ACET is the stock ticker symbol of Adicet Bio, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Adicet Bio, Inc. (ACET)?

As of Tue Feb 27 2024, market cap of Adicet Bio, Inc. is 103.16 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ACET stock?

You can check ACET's fair value in chart for subscribers.

What is the fair value of ACET stock?

You can check ACET's fair value in chart for subscribers. The fair value of Adicet Bio, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Adicet Bio, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ACET so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Adicet Bio, Inc. a good stock to buy?

The fair value guage provides a quick view whether ACET is over valued or under valued. Whether Adicet Bio, Inc. is cheap or expensive depends on the assumptions which impact Adicet Bio, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ACET.

What is Adicet Bio, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Feb 27 2024, ACET's PE ratio (Price to Earnings) is -1.5 and Price to Sales (PS) ratio is 1.75. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ACET PE ratio will change depending on the future growth rate expectations of investors.